Quantcast

Latest Thousand Oaks, California Stories

2014-09-05 16:23:16

THOUSAND OAKS, Calif., Sept. 5, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 10, 2014, at the Grand Hyatt New York in New York City, beginning at 9:10 a.m. ET. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast...

2014-08-19 08:29:36

With locations in Thousand Oaks, Simi Valley, Oxnard and Camarillo, West Coast ENT provides exceptional ear, nose and throat services for patients. THOUSAND OAKS, Calif., Aug. 19, 2014 /PRNewswire-iReach/ -- While the West Coast's mild winters make for comfortable year-round temperatures, they lead to extended pollination seasons. This leads to longer bouts of the itching, sneezing, stuffiness and hay fever that can accompany a California later summer/fall. If West Coast residents...

2014-08-13 16:26:02

THOUSAND OAKS, Calif., Aug. 13, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) initiated a voluntary recall on June 26, 2014 for nine packaged lots of Aranesp(®) (darbepoetin alfa) (500 mcg) prefilled syringes from non-U.S. distributors, wholesalers and a number of hospital pharmacies due to the potential presence of cellulose and/or polyester particles observed in a small number of syringes during a routine quality examination. Lots 1042847, 1044141A, 1044141C, 1044141D, 1046891A, 1046891B,...

2014-08-13 16:25:38

THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Aug. 13, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that the Phase 3 clinical trial FOCUS (CarFilzOmib for AdvanCed Refractory MUltiple Myeloma European Study) did not meet its primary endpoint of improving overall survival (OS) (HR=0.975, 95 percent CI, 0.760, 1.249). The 315-patient, open-label study evaluated single-agent Kyprolis(®) (carfilzomib) for Injection...

2014-07-24 16:26:54

THOUSAND OAKS, Calif., July 24, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Tuesday, July 29, 2014, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team. Live audio of...

2014-06-16 16:25:14

Lung-MAP Trial Will Test Five Investigational Approaches, Including Amgen's Rilotumumab, an Investigational Fully Human Monoclonal Antibody THOUSAND OAKS, Calif., June 16, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that it will collaborate with the National Cancer Institute (NCI), part of the National Institutes of Health, and other public and private sector partners on the Lung Master Protocol (Lung-MAP), a groundbreaking new clinical trial program that will use...

2014-06-10 16:26:06

SANTA MONICA, Calif., June 10, 2014 /PRNewswire/ -- Kite Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced the expansion of Kite's research and development leadership team with the appointments of William Y. Go, M.D., Ph.D., as Senior Director, Clinical Development and Jeff Aycock as Senior Director, Clinical Operations....

2014-06-09 16:25:38

THOUSAND OAKS, Calif., June 9, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the appointment of David W. Meline as executive vice president and chief financial officer (CFO), effective July 21, 2014. He will be responsible for Amgen's finance and investor relations operations, reporting to Robert A. Bradway, chairman and chief executive officer. Meline will succeed Michael A. Kelly, who served as acting CFO since January 2014. Meline, 56, joins Amgen from 3M Company, where...

2014-06-06 16:23:57

THOUSAND OAKS, Calif., June 6, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs Global Healthcare Conference at 1:20 p.m. PT on Wednesday, June 11, 2014, at the Terranea Resort in Rancho Palos Verdes, Calif. Anthony C. Hooper, executive vice president of Global Commercial Operations at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of...

2014-06-02 08:30:06

New Chief Medical Officer Brings Wealth of Experience in Innovative Therapies in Oncology SANTA MONICA, Calif., June 2, 2014 /PRNewswire/ -- Kite Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced the appointment of David D. Chang, M.D., Ph.D., as Executive Vice President, Research and Development, and Chief Medical Officer. Dr. Chang brings a substantial...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related